Hidradenitis Suppurativa

The PBS subsidises adalimumab for patients with moderate to severe hidradenitis suppurativa.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with adalimumab under the National Health Act 1953, section 85 for patients with moderate to severe hidradenitis suppurativa (HS).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing adalimumab.

Treatment specifics

To be eligible for PBS subsidised treatment with adalimumab, patients must be treated by a dermatologist.

Authority applications

Applying for initial or recommencement of treatment

Apply for initial or recommencement authority approval to prescribe PBS subsidised adalimumab to treat moderate to severe HS in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Apply for continuing authority approval to prescribe PBS subsidised adalimumab to treat moderate to severe HS in writing and either:

All written applications must include the completed:

After we approve the first application for continuing treatment, subsequent continuing treatment with PBS subsidised biosimilar brands of biological agents are Authority Required (Streamlined). They don’t need authority approval from us for listed quantity and repeats.

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 April 2021